JPWO2023020625A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2023020625A5 JPWO2023020625A5 JP2024509425A JP2024509425A JPWO2023020625A5 JP WO2023020625 A5 JPWO2023020625 A5 JP WO2023020625A5 JP 2024509425 A JP2024509425 A JP 2024509425A JP 2024509425 A JP2024509425 A JP 2024509425A JP WO2023020625 A5 JPWO2023020625 A5 JP WO2023020625A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- fusion protein
- acid sequence
- tgf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000037865 fusion proteins Human genes 0.000 claims description 40
- 108020001507 fusion proteins Proteins 0.000 claims description 40
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 239000012634 fragment Substances 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 6
- 101000961149 Homo sapiens Immunoglobulin heavy constant gamma 4 Proteins 0.000 claims description 2
- 102100039347 Immunoglobulin heavy constant gamma 4 Human genes 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 29
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 9
- 239000000047 product Substances 0.000 claims 9
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 9
- 108091005735 TGF-beta receptors Proteins 0.000 claims 8
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 230000000259 anti-tumor effect Effects 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 230000027455 binding Effects 0.000 claims 6
- 229940127089 cytotoxic agent Drugs 0.000 claims 6
- 239000013066 combination product Substances 0.000 claims 4
- 229940127555 combination product Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000003950 B-cell lymphoma Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 3
- 208000034578 Multiple myelomas Diseases 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 208000007452 Plasmacytoma Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 3
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 3
- KSMZEXLVHXZPEF-UHFFFAOYSA-N 1-[[4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine Chemical group COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)C=CN=C2C=C1OCC1(N)CC1 KSMZEXLVHXZPEF-UHFFFAOYSA-N 0.000 claims 2
- 229940124618 Anlotinib Drugs 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 2
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 claims 2
- 229960003784 lenvatinib Drugs 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 101000840257 Homo sapiens Immunoglobulin kappa constant Proteins 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 101710138871 Ig gamma-1 chain C region Proteins 0.000 claims 1
- 102100039345 Immunoglobulin heavy constant gamma 1 Human genes 0.000 claims 1
- 102100029572 Immunoglobulin kappa constant Human genes 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims 1
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 claims 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims 1
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 claims 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 claims 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- -1 mesylate salt Chemical class 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110961038 | 2021-08-20 | ||
| CN202110961038.5 | 2021-08-20 | ||
| PCT/CN2022/113882 WO2023020625A1 (zh) | 2021-08-20 | 2022-08-22 | 包含抗TIGIT抗体和TGF-βR的融合蛋白、其药物组合物及用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024532836A JP2024532836A (ja) | 2024-09-10 |
| JPWO2023020625A5 true JPWO2023020625A5 (https=) | 2024-11-12 |
| JP2024532836A5 JP2024532836A5 (https=) | 2024-11-12 |
Family
ID=85239528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024509425A Pending JP2024532836A (ja) | 2021-08-20 | 2022-08-22 | 抗ＴＩＧＩＴ抗体及びＴＧＦ－βＲを含む融合タンパク質、並びにその医薬組成物及び使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250319169A2 (https=) |
| EP (1) | EP4389771A4 (https=) |
| JP (1) | JP2024532836A (https=) |
| KR (1) | KR20240046905A (https=) |
| CN (1) | CN116003625A (https=) |
| AU (1) | AU2022330896A1 (https=) |
| CA (1) | CA3229166A1 (https=) |
| IL (1) | IL310541A (https=) |
| MX (1) | MX2024002147A (https=) |
| WO (1) | WO2023020625A1 (https=) |
| ZA (1) | ZA202401813B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021372706A1 (en) * | 2020-10-26 | 2023-06-08 | Akeso Biopharma, Inc. | Anti-tigit antibody, and pharmaceutical composition and use thereof |
| JP2026508210A (ja) * | 2023-02-20 | 2026-03-10 | 中山康方生物医▲藥▼有限公司 | ＴＧＦ－βＲＩＩ細胞外領域断片を含む融合タンパク質、その医薬組成物、およびその使用 |
| CN119613559B (zh) * | 2023-09-14 | 2026-01-02 | 中山康方生物医药有限公司 | 药物组合及用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JO3096B1 (ar) * | 2008-11-07 | 2017-03-15 | Imclone Llc | الأجسام المضادة لمستقبل ii مضاد tgfb |
| CN107207594B (zh) * | 2014-12-23 | 2019-05-07 | 百时美施贵宝公司 | 针对tigit的抗体 |
| EP3349792A1 (en) * | 2015-09-14 | 2018-07-25 | Compass Therapeutics LLC | Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf- |
| CA2994858C (en) * | 2015-09-25 | 2024-01-23 | Genentech, Inc. | Anti-tigit antibodies and methods of use |
| JP7068169B2 (ja) * | 2016-01-08 | 2022-05-16 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 条件付活性ヘテロ二量体ポリペプチド及びその使用方法 |
| WO2017152088A1 (en) * | 2016-03-04 | 2017-09-08 | JN Biosciences, LLC | Antibodies to tigit |
| AU2018264455B2 (en) * | 2017-05-12 | 2024-12-12 | Jiangsu Hengrui Medicine Co., Ltd. | Fusion protein containing TGF-beta receptor and medicinal uses thereof |
| US11512129B2 (en) * | 2017-09-29 | 2022-11-29 | Jiangsu Hengrui Medicine Co., Ltd. | TIGIT antibody, antigen-binding fragment thereof, and medical use thereof |
| JP7348899B2 (ja) * | 2017-12-08 | 2023-09-21 | マレンゴ・セラピューティクス，インコーポレーテッド | 多重特異性分子及びその使用 |
| KR20200109313A (ko) * | 2018-01-15 | 2020-09-22 | 난징 레전드 바이오테크 씨오., 엘티디. | Tigit에 대한 항체 및 이의 변이체 |
| CN114555099A (zh) * | 2019-06-23 | 2022-05-27 | 广东天科雅生物医药科技有限公司 | 抗alpp car-t细胞疗法 |
| EP4054633A1 (en) * | 2019-11-05 | 2022-09-14 | Merck Patent GmbH | Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer |
| WO2021093760A1 (zh) * | 2019-11-12 | 2021-05-20 | 江苏恒瑞医药股份有限公司 | 含有TGF-β受体的融合蛋白及其医药用途 |
| US20220409684A1 (en) * | 2019-11-18 | 2022-12-29 | The Brigham And Women's Hospital, Inc. | Codon optimized new generation regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use |
| AU2021372706A1 (en) * | 2020-10-26 | 2023-06-08 | Akeso Biopharma, Inc. | Anti-tigit antibody, and pharmaceutical composition and use thereof |
| CN114106182B (zh) * | 2022-01-26 | 2022-05-17 | 中山康方生物医药有限公司 | 抗tigit的抗体及其用途 |
| CN114181310B (zh) * | 2022-02-14 | 2022-07-05 | 中山康方生物医药有限公司 | 抗tigit抗体、其药物组合物及用途 |
-
2022
- 2022-08-22 AU AU2022330896A patent/AU2022330896A1/en active Pending
- 2022-08-22 WO PCT/CN2022/113882 patent/WO2023020625A1/zh not_active Ceased
- 2022-08-22 CA CA3229166A patent/CA3229166A1/en active Pending
- 2022-08-22 IL IL310541A patent/IL310541A/en unknown
- 2022-08-22 EP EP22857934.8A patent/EP4389771A4/en active Pending
- 2022-08-22 KR KR1020247008893A patent/KR20240046905A/ko active Pending
- 2022-08-22 CN CN202211006660.1A patent/CN116003625A/zh active Pending
- 2022-08-22 US US18/684,899 patent/US20250319169A2/en active Pending
- 2022-08-22 MX MX2024002147A patent/MX2024002147A/es unknown
- 2022-08-22 JP JP2024509425A patent/JP2024532836A/ja active Pending
-
2024
- 2024-03-01 ZA ZA2024/01813A patent/ZA202401813B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102937285B1 (ko) | 신규 항-pd-l1 항체 | |
| CA2987118C (en) | A pdl-1 antibody, pharmaceutical composition thereof and use thereof | |
| CN101868478B (zh) | 巨噬细胞刺激蛋白质受体(ron)的抑制及其治疗方法 | |
| EP4151652A1 (en) | Anti-cd73 antibody and use thereof | |
| CN114181310B (zh) | 抗tigit抗体、其药物组合物及用途 | |
| KR20210093879A (ko) | 항-cldn18.2 항체 및 이의 용도 | |
| AU2017279046A1 (en) | Therapeutic uses of a c-Raf inhibitor | |
| US11680102B2 (en) | Anti-BAFF receptor antibodies and uses thereof | |
| CN115785268B (zh) | 抗cd47抗体及其用途 | |
| CA3226242A1 (en) | Pharmaceutical composition and use | |
| JP2021533770A5 (https=) | ||
| US9358288B2 (en) | Antibody combinations and use of same for treating cancer | |
| EP4506360A1 (en) | Anti-pvrig antibody, pharmaceutical composition thereof and use thereof | |
| CN116925233A (zh) | 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途 | |
| JPWO2020108611A5 (https=) | ||
| JPWO2022042719A5 (https=) | ||
| JPWO2023020625A5 (https=) | ||
| JPWO2022083723A5 (https=) | ||
| EP4725968A1 (en) | Anti-gpc3 antibody or antigen-binding fragment and use thereof | |
| WO2016163433A1 (ja) | 抗ｆｇｆｒ２抗体と他剤を含む組成物 | |
| JPWO2020218951A5 (https=) | ||
| JPWO2023051683A5 (https=) | ||
| RU2024103139A (ru) | Слитый белок, содержащий антитело против TIGIT и TGF-βR, фармацевтическая композиция и ее применение | |
| JPWO2023186081A5 (https=) | ||
| JPWO2023186092A5 (https=) |